Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | ALPG | P10696 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359225 | 1.00 | MAPT (1.00) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL9326802 | 0.81 | RAB9A (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL2609271 | 0.81 | MAPT (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL2609270 | 0.81 | MAPT (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL28642636 | 0.81 | KDM4E (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL28427466 | 0.81 | MAPT (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL3776968 | 0.81 | ALDH1A1 (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29052306 | 0.81 | MAPT (0.68) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29386070 | 0.79 | MAPT (0.64) | MAPTRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL9326807 | 0.78 | MEN1 (0.63) | MAPTRAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| CN-116893237-A | Metabolic marker related to neonatal pneumonia and myocardial damage and application thereof | 大连大学 | 2023-10-17 | — | — | CN | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| CN-113441135-B | Preparation method of 2-amino-3H-phenoxazin-3-one or derivative thereof | 兰州大学 | 2022-09-20 | — | — | CN | claimed |
| CN-113441135-A | Preparation method of 2-amino-3H-phenoxazin-3-one or derivative thereof | 兰州大学 | 2021-09-28 | — | — | CN | claimed |
| CN-111205238-B | Method for generating 2-aminophenol oxazine-3-ketone compound by catalyzing oxidation of molecular oxygen in aqueous phase | 郑州大学 | 2021-08-06 | — | — | CN | claimed |
| CN-111205238-A | Method for generating 2-aminophenol oxazine-3-ketone compound by catalyzing oxidation of molecular oxygen in aqueous phase | 郑州大学 | 2020-05-29 | — | — | CN | claimed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | claimed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | claimed |
| US-20100324285-A1 | ANTIINFLAMMATORY AGENT COMPRISING 2-AMINOPHENOL OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2010-12-23 | — | — | US | claimed |
| EP-2098228-A1 | ANTIINFLAMMATORY AGENT COMPRISING 2-AMINOPHENOL OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2009-09-09 | — | — | EP | claimed |
| WO-2009003625-A1 | AMINOPHENOXAZINONE AS AN ANTI-TUMOUR AND ANTI-INFLAMMATORY AGENT | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKILINIKUM (DE) | 2009-01-08 | — | — | WO | claimed |
| JP-1086891-A | — | — | None | — | — | JP | disclosed |
| US-12606767-B2 | 1,4-benzoxazine compounds and lubricant compositions containing the same | THE LUBRIZOL CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| EP-0449557-A2 | Recovery of values from cereal wastes | Her Majesty in Right of Canada as represented by the Minister of Agriculture Canada (CA) | 1991-10-02 | — | — | EP | disclosed |
| JP-S6486891-A | PRODUCTION OF 2-AMINOPHENOXAZIN 3-ONE | TOMOTA AKIO | 1989-03-31 | — | — | JP | disclosed |
| US-4370142-A | Hair-dyeing compositions based on para-phenylenediamine and ortho-aminophenol | L'OREAL (FR) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324285-A1 | ANTIINFLAMMATORY AGENT COMPRISING 2-AMINOPHENOL OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT | PTGES2, PTGS2, PTGES | MAPT 2218/4885RAB9A 4632/4885MEN1 4848/4885 |
| US-12606767-B2 | 1,4-benzoxazine compounds and lubricant compositions containing the same | PRDX4, PRDX1, GPX4 | MAPT 1299/4885RAB9A 4610/4885MEN1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.